Dr. Jianwei Zhu,CEO & CSO of Jecho Bio was invited to Tianjin University of Science and Technology
Dr. Jianwei Zhu Chief Executive Officer and Chief Scientific Officer of Jecho Biopharmaceuticals Co., Ltd. was invited to Tianjin University of Science and Technology (TUST) for a seminar to graduare students and faculties. The event was organized by local biomedical science community and School of Bio-engineering of TUST.
It was on Satauday and over 100 students and faculties attended the event. The seminar was focused on technology innovation and novel biotherapeutics development based on Dr. Zhu's broard experiences and achievements in the field. Brief discussion on strategical collaborations between Jecho and the University was held after the seminar.
Jecho Biopharmacals is the first company invested in China by Jecho Laboratories, Inc., an American biopharmaceutical company. Located in Sino-Singapore Tianjin Eco-City in the Tianjin Binhai New District, it is now establishing a world-class R&D and production base for a wide range of biological medicines. The base will be constructed in two phases. It focuses on researching, developing and producing innovative biological medicine to treat critical illnesses ( i.e. cancer and infectious diseases). At present, the first-phase construction has come to the final stage. The project is estimated to generate a value of more than 500 million RMB and create 1500 jobs locally when completed. At the same time, the base willbecome an addition to the biopharmaceutical industrial chain in northern China, which will certainly create enormous returns and significant benefits.
杰科生物是美国生物医药公司Jecho Laboratories, Inc.在中国投资成立的第一家企业，位于天津滨海新区中新天津生态城，正在建设达到世界先进水平的生物医药研发及生产基地。基地将分为两期建设，重点研发生产治疗人类重大疾病（如：癌症和感染性疾病）的创新型生物药物。目前，项目一期工程已接近尾声。待整体项目建成投产后，预估产值达五十亿元以上；可为当地提供约1500个就业岗位。同时丰富了华北地区的生物医药产业链，未来必能创造出巨大的经济效益和良好的社会效益。